Irsko - angličtina - HPRA (Health Products Regulatory Authority)

neutec inhaler ireland limited - ipratropium bromide monohydrate; salbutamol sulfate - nebuliser solution - salbutamol and ipratropium bromide

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate -

Kanada - angličtina - Health Canada

teva canada limited - salbutamol (salbutamol sulfate) - metered-dose aerosol - 100mcg - salbutamol (salbutamol sulfate) 100mcg - selective beta 2-adrenergic agonists

Kanada - angličtina - Health Canada

sandoz canada incorporated - salbutamol (salbutamol sulfate) - solution - 5mg - salbutamol (salbutamol sulfate) 5mg - selective beta 2-adrenergic agonists

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - salbutamol sulfate 120ug equivalent to salbutamol 100 µg;   - aerosol inhaler, metered dose - 100 mcg - active: salbutamol sulfate 120ug equivalent to salbutamol 100 µg   excipient: ethanol norflurane oleic acid

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

rex medical ltd - salbutamol sulfate 0.12mg equivalent to 100 mcg salbutamol - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 0.12mg equivalent to 100 mcg salbutamol excipient: ethanol norflurane oleic acid - salbutamol sulphate is indicated for the prevention and treatment of bronchospasm and acts on the ?2 (beta-2) adrenoceptors of bronchial muscle at therapeutic doses, with little or no action on the ?1 (beta-1) adrenoceptors of the heart. with its fast onset of action, it is particularly suitable for the management and prevention of attack in mild asthma and for the treatment of acute exacerbations in moderate to severe asthma. patients with unstable or severe asthma should not rely on bronchodilators as the main or only form of treatment. severe asthma requires regular medical assessment as death may occur. patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and pef values below 60% (predicted at baseline) with greater than 30% variability, usually not returning entirely to normal after a bronchodiliator. together with corticosteroid treatment, salair inhaler provides essential rescue medication for severe asthmatics in treating acute exacerbations. urgent treatment and medical advice is required immediately - if the patient fails to respond rapidly or fully to the rescue medication. salair provides short-acting (4-6 hours) bronchodiliation with fast onset in reversible airways obstruction disease appropriate for emphysema, asthma and chronic bronchitis. it is suitable for long-term use in the relief and prevention of asthma symptoms. salair should be utilized to alleviate symptoms when they happen and to prevent them in those circumstances recognised by the patient to precipitate an asthmatic attack (e.g. before exercise or unavoidable allergen exposure). salair is particularly valuable as rescue medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - salbutamol sulfate 0.4 mg/ml - elixir - 2mg/5ml - active: salbutamol sulfate 0.4 mg/ml

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - salbutamol sulfate 1 mg/ml - solution for infusion - 5mg/5ml - active: salbutamol sulfate 1 mg/ml

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - salbutamol sulfate 0.5 mg/ml - solution for injection - 0.5 mg/ml - active: salbutamol sulfate 0.5 mg/ml

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

origen pharmaceuticals limited - salbutamol sulfate 0.4 mg/ml - solution for inhalation - 2mg/5ml - active: salbutamol sulfate 0.4 mg/ml